JointHealth™ express September 14, 2012
Let BC PharmaCare hear “Your Voice”
Do you live with severe granulomatosis with polyangiitis (GPA, also known as Wegener’s granulomatosis) and microscopic polyangiitis (MPA)? Do you care for someone, or does your organization represent people, with this medical condition? You can provide feedback to British Columbia’s Ministry of Health about rituximab (Rituxan®) for the treatment of GPA or MPA, which are forms of vasculitis, via a website called Your Voice.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
Let BC PharmaCare hear “Your Voice”
Do you live with severe granulomatosis with polyangiitis (GPA, also known as Wegener’s granulomatosis) and microscopic polyangiitis (MPA)? Do you care for someone, or does your organization represent people, with this medical condition? You can provide feedback to British Columbia’s Ministry of Health about rituximab (Rituxan®) for the treatment of GPA or MPA, which are forms of vasculitis, via a website called Your Voice.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for rituximab: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here. (Patient groups are required to register their name with the Ministry of Health before making their submission.)
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.